MedTrace Logo

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

NCT06136195 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-08-03

No results posted yet for this study

Summary

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

Conditions

  • Alcohol Consumption
  • Heavy Drinker
  • Alcohol Use Disorder (AUD)

Interventions

DRUG

Mavoglurant

The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Suchitra Krishnan, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06136195 on ClinicalTrials.gov